Journal of Clinical Oncology
Articles in this Issue
Clinicopathologic features, treatment patterns, and outcomes of microsatellite instability–high (MSI-H) gastric (GC) and gastroesophageal junction adenocarcinoma (GEJ): A single-center retrospective analysis.
445 Background: The biologically distinct subtype of MSI-H GC/GEJ has prognostic and therapeutic implications. Immunothera...
Phase I study of ART-123 in combination with FOLFOX + bevacizumab for patients with metastatic colorectal cancer.
111 Background: Persistent peripheral neuropathy is a common adverse event (AE) of oxaliplatin. ART-123, a recombinant hum...
Mortality and 30-day readmissions among hepatocellular carcinoma patients hospitalized for portal vein thrombosis: A nationwide analysis.
505 Background: Portal vein thrombosis (PVT), although considered rare in the general population, has a prevalence that va...
Circulating free RNA (cfRNA) as a predictive tool for immunotherapy benefit in mismatch-repair-deficient colorectal cancer (dMMR CRC).
219 Background: In dMMR CRC, predictive biomarkers to guide the use of anti-PD1 single-agent versus anti-PD1 plus anti-CTL...
Molecular characterization of resected non-metastatic pancreatic cancer (PC) based on <i>KRAS</i> status.
776 Background: Surgery is the only potentially curative option for PC. However, only a minority of patients (pts) undergo...
Prognostic significance of Claudin18.2 expression in gastric cancer: A large single-center cohort and meta-analysis.
449 Background: Claudin 18.2 (CLDN18.2) is a novel treatment target for patients with unresectable or stage IV gastric can...
Prognostic value of presurgical circulating tumor DNA (ctDNA) levels and other clinical factors in colon cancer.
221 Background: While post-surgical ctDNA is a known biomarker for risk of recurrence in colon cancer patients (pts), the...
Efficacy of capecitabine and temozolomide (CAPTEM) in patients with gastrointestinal neuroendocrine tumors (GI-NETs).
637 Background: CAPTEM is a treatment option for patients (pts) with well-differentiated pancreatic NETs based on the phas...
Multiomic analysis and oncologic outcomes in pancreatic cancer by PIN1 expression.
784 Background: Proline isomerase (PIN1) is a novel investigational target and is associated with desmoplastic stroma, an...
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01- HCRN GI23-643.
TPS260 Background: Pembrolizumab is one of the standard front-line immune checkpoint inhibitors (ICI) therapies for patien...
Genetic variation and regulation of MICA alters natural killer cell-mediated immunosurveillance in early-onset colorectal cancer.
207 Background: One of the most concerning trends in oncology is the rapid increase in the incidence of early-onset cancer...
Quantitative radiomics-based biomarker discovery for prognostic stratification in gastroesophageal cancer: Insights from the Cancer Moonshot Biobank Imaging Cohort.
438 Background: Radiomics has emerged as a promising approach for non-invasive biomarker discovery in oncology. However, i...
Investigating the association of inflammatory markers with clinical outcomes of patients with KRAS and BRAF V600E-mutated colorectal cancer.
200 Background: Patients with colorectal cancer (CRC), particularly those with BRAF and KRAS mutations, often present with...
How about the impact of tumor regression grade on pancreatic adenocarcinoma survival?
779 Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies, with a 5-year survival...
Frequency of peritoneal metastasis (PM) as exclusion criteria in clinical trials of gastrointestinal (GI) cancers.
297 Background: The peritoneum is a common and devastating site of metastases for several types of gastrointestinal cancer...
Genomic characterization of resectable pancreatic ductal adenocarcinoma (r-PDAC) on the NeoPancONE trial.
774 Background: The optimal approach in r-PDAC remains unclear. Perioperative Modified FOLFIRINOX (mFFX) is increasingly u...
First-line immunotherapy plus gemcitabine–cisplatin versus chemotherapy alone in advanced cholangiocarcinoma: A meta-analysis.
573 Background: Cholangiocarcinoma (CAA) is a rare but highly aggressive malignancy arising from the bile duct epithelium,...
Effect of BRCA2, BRAF, APC, and PTEN expression on the prognostic significance of surgical margin status in primary gastric adenocarcinoma.
455 Background: Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer-related mortalit...
Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase II trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer.
719 Background: Metastatic pancreatic cancer (mPC) is one of the most challenging malignancies worldwide. While nab-paclit...
Preliminary results of tumor-informed minimal residual disease detection in pancreatic cancer patients following curative resection and FOLFIRINOX adjuvant chemotherapy.
753 Background: Circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) testing has emerged as a powerful progn...
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma: Survival analysis.
350 Background: Based on the JCOG1109 trial, the combination of neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) f...
Metastatic patterns and outcomes among early-onset versus average-onset gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Insights from a multicenter database analysis.
621 Background: The incidence of early-onset GEP-NETs (EO, <50 years) is rising, with data suggesting better outcomes c...
Inflammatory and immune marker dynamics following intratumoral alpha dart for pancreatic cancer.
771 Background: Immune markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and system...
Impact of postoperative ctDNA dynamics on eligibility for the ALTAIR randomized trial in patients with colorectal cancer: Implications for clinical trial enrollment.
12 Background: Postoperative circulating tumor DNA (ctDNA) positivity is strongly associated with increased recurrence ris...
Improvement of survival in advanced gastric cancer over 15 years: Real-world analysis by 5-year periods.
375 Background: The prognosis of advanced gastric cancer (AGC) has gradually improved with the development of systemic che...